Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009

Cancer

Volumn 118, Issue 22, 2012, Pages 5473-5480

  Ceresini, Graziano ^a   Corcione, Luigi ^b   Michiara, Maria ^a,c   Sgargi, Paolo ^c   Teresi, Giulio ^a   Gilli, Annalisa ^c   Usberti, Elisa ^a   Silini, Enrico ^b   Ceda, Gian Paolo ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c Tumor Registry of the Province of Parma   (Italy)

Author keywords

cancer; histotypes; incidence; population; thyroid

Indexed keywords

ADOLESCENT; ADULT; AGED; CANCER INCIDENCE; CANCER REGISTRY; CANCER STAGING; CHILD; FEMALE; HISTOPATHOLOGY; HUMAN; INFANT; IODINE DEFICIENCY; ITALY; MALE; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; TALL CELL VARIANT PAPILLARY THYROID CARCINOMA; THYROID CANCER; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PARAFOLLICULAR CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

ADENOCARCINOMA, FOLLICULAR; CARCINOMA; FEMALE; HUMANS; INCIDENCE; IODINE; ITALY; MALE; PROGNOSIS; REGISTRIES; SURVIVAL RATE; THYROID NEOPLASMS;

EID: 84868209466     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27591     Document Type: Review

References (49)

1. Burgess JR, Tucker P,. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006; 16: 47-53.
2. Colonna M, Guizard AV, Schvartz C, et al. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983-2000). Eur J Cancer. 2007; 43: 891-900.
3. Davies L, Welch HG,. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006; 295: 2164-2167.
4. Leenhardt L, Grosclaude P, Cherie-Challine L,; Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004; 14: 1056-1060.
5. Liu S, Semenciw R, Ugnat AM, Mao Y,. Increasing thyroid cancer incidence in Canada, 1970-1996: time trends and age-period-cohort effects. Br J Cancer. 2001; 85: 1335-1339.
6. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW,. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf). 2005; 62: 156-162.
7. Smailyte G, Miseikyte-Kaubriene E, Kurtinaitis J,. Increasing thyroid cancer incidence in Lithuania in 1978-2003. BMC Cancer. 2006; 6: 284.
8. Mitchell I, Livingston EH, Chang AY, et al. Trends in thyroid cancer demographics and surgical therapy in the United States. Surgery. 2007; 142: 823-828.
9. Sherman S, Fagin J,. Why thyroid cancer? Thyroid. 2005; 15: 303-304.
10. Boyle P, Ferlay J,. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16: 481-488.
11. AIRT Working Group. Italian cancer figures-report 2006: incidence, mortality and estimates 2006. Epidemiol Prev. 2006; 30 (1 suppl 2): 80-81.
12. Leenhardt L, Bernier MO, Boin-Pineau MH, et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol. 2004; 150: 133-139.
13. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008.
14. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93: 824-842.
15. Chen AY, Jemal A, Ward EM,. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115: 3801-3807.
16. Enewold L, Zhu K, Ron E, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev. 2009; 18: 784-791.
17. Ceresini G, Milli B, Morganti S, et al. Effect of estrogen therapy for 1 year on thyroid volume and thyroid nodules in postmenopausal women. Menopause. 2008; 15: 326-331.
18. Roti E, Bianconi L, Gardini E, et al. Postpartum thyroid dysfunction in an Italian population residing in an area of mild iodine deficiency. J Endocrinol Invest. 1991; 14: 669-674.
19. Ghossein R, Livolsi VA,. Papillary thyroid carcinoma tall cell variant. Thyroid. 2008; 18: 1179-1181.
20. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors. 6th ed. New York, NY: Springer-Verlag; 2002.
21. Mazeh H, Samet Y, Hochstein D, et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg. 2011; 201: 770-775.
22. Dal Maso L, Lise M, Zambon P, et al. AIRTUM Working Group. Incidence of thyroid cancer in Italy, 1991-2005: time trends and age-period-cohort effects. Ann Oncol. 2011; 22: 957-963.
23. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19: 1167-1214.
24. Elisei R, Molinaro E, Agate L, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab. 2010; 95: 1516-1527.
25. Jovanovic L, Delahunt B, McIver B, Eberhardt NL, Grebe SK,. Most multifocal papillary thyroid carcinomas acquire genetic and morphotype diversity through subclonal evolution following the intra-glandular spread of the initial neoplastic clone. J Pathol. 2008; 215: 145-154.
26. Giannini R, Ugolini C, Lupi C, et al. The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007; 92: 3511-3516.
27. Mete O, Asa SL,. Pathological definition and clonical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. Mod Pathol. 2011; 24: 1545-1552.
28. Pellegriti G, De Vathaire F, Scollo C, et al. Papillary thyroid cancer incidence in the volcanic area of Sicily. J Natl Cancer Inst. 2009; 101: 1575-1583.
29. Fortner J, George P, Sternberg S,. Induced and spontaneous thyroid cancer in the Syrian hamster. Endocrinology. 1960; 6: 364-376.
30. Schaller RT Jr, Stevenson JK,. Development of carcinoma of the thyroid in iodine-deficient mice. Cancer. 1966; 19: 1063-1080.
31. Laurberg P, Nohr SB, Pedersen KM, et al. Thyroid disorders in mild iodine deficiency. Thyroid. 2000; 10: 951-963.
32. Feldt-Rasmussen U,. Iodine and cancer. Thyroid. 2001; 11: 483-486.
33. Burgess JR,. Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997). Thyroid. 2002; 12: 141-149.
34. Pettersson B, Coleman MP, Ron E, Adami HO,. Iodine supplementation in Sweden and regional trends in thyroid cancer incidence by histopathologic type. Int J Cancer. 1996; 65: 13-19.
35. Bacher-Stier C, Riccabona G, Totsch M, Kemmler G, Oberaigner W, Moncayo R,. Incidence and clinical characteristics of thyroid carcinoma after iodine prophylaxis in an endemic goiter country. Thyroid. 1997; 7: 733-741.
36. Rolon PA,. Cancer of the thyroid in an area of endemic goiter. "Papillarization" with prophylactic iodization [in French]. Ann Pathol. 1986; 6: 170-175.
37. Shi YF, Zou MJ, Schmidt H, et al. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res. 1991; 51: 2690-2693.
38. Smyth PP,. Iodine and anaplastic thyroid carcinoma. Thyroid. 2010; 20: 581-582.
39. Liu XH, Chen GG, Vlantis AC, van Hasselt CA,. Iodine mediated mechanisms and thyroid carcinoma. Crit Rev Clin Lab Sci. 2009; 46: 302-318.
40. Hawk WA, Hazard JB,. The many appearances of papillary carcinoma of the thyroid. Cleve Clin Q. 1976; 43: 207-215.
41. Michels JJ, Jacques M, Henry-Amar M, Bardet S,. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol. 2007; 38: 212-219.
42. Ruter A, Nishiyama R, Lennquist S,. Tall-cell variant of papillary thyroid cancer: disregarded entity? World J Surg. 1997; 21: 15-20; discussion 20-21.
43. Ghossein RA, Leboeuf R, Patel KN, et al. Tall cell variant of papillary thyroid carcinoma without extrathyroid extension: biologic behavior and clinical implications. Thyroid. 2007; 17: 655-661.
44. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF,. Invasive Hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc. 1984; 59: 851-855.
45. Hundahl SA, Fleming ID, Fremgen AM, Menck HR,. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer. 1998; 83: 2638-2648.
46. Rosen IB, Luk S, Katz I,. Hurthle cell tumor behavior: dilemma and resolution. Surgery. 1985; 98: 777-783.
47. Arganini M, Behar R, Wu TC, et al. Hurthle cell tumors: a twenty-five-year experience. Surgery. 1986; 100: 1108-1115.
48. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA,. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab. 1988; 67: 501-508.
49. Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM,. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc. 1991; 66: 11-22.